Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese-Bullock, Margaret Mehren, Naomi B. Haas, Merrick I. Ross, Lynn T. Dengel and Craig L. Slingluff ()
Additional contact information
Emily K. Ninmer: University of Virginia
Hong Zhu: University of Virginia
Kimberly A. Chianese-Bullock: University of Virginia
Margaret Mehren: Fox Chase Cancer Center
Naomi B. Haas: Fox Chase Cancer Center
Merrick I. Ross: MD Anderson Cancer Center
Lynn T. Dengel: University of Virginia
Craig L. Slingluff: University of Virginia

Nature Communications, 2025, vol. 16, issue 1, 1-2

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-63690-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63690-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-63690-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().